PDE5A and erectile dysfunction: Using the US FAERS, ten years of industry and non-industry reports of adverse cardiovascular events or mortality associated with three phosphodiesterase type-5 inhibitors (PDE5-i) (sildenafil, tadalafil, and vardenafil), used to treat erectile dysfunction, were investigated.